Experimental HIV-1 vaccine regimen is safe and elicits a robust immune response according to results of a Phase I/IIa clinical trial.
Browsing: Basic > Pre-clinical Trials
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
A high-fiber diet can boost the immune response and increase survival in mice infected with influenza virus, according to new research.
Two genetically-modified broadly-neutralizing antibodies have been demonstrated to elicit long-term protection against an HIV-like virus in rhesus macaques, with a Phase I clinical trial now underway.
In this interview, we speak to Dr. Bryan Kraft, an Assistant Professor of Medicine at Duke University, about his research into carbon monoxide as a potential therapy to treat ARDS and the clinical trial for this therapy that is currently underway.
Learn more about the top news stories of the week in our round-up, including new guidance for drug-resistant infections and a Phase I trials for a MERS treatment.
Researchers have developed a drug delivery system that could allow antiretroviral drugs for HIV to be administered only once a week, potentially making it easier for patients to adhere to drug regimens.
MedChemNet and Infectious Diseases Hub recently attended the first two days of the 19th RSC / SCI Medicinal Chemistry Symposium. Here, you can catch up on the session delving into drug discovery for the neglected tropical diseases.
Researchers have discovered that antibodies taken from dengue virus infected individuals are effective in treating Zika infection – a closely related flavivirus – in rodents.
A novel trispecific antibody has been developed by researchers from the NIH and Sanofi, demonstrating effectiveness against of 99% of HIV strains and protective immunity in non-human primates.